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1. Introduction  
Paclitaxel, better known as Taxol® its original name and now trade mark, and its direct 
derivatives, has been one of the most effective drugs used against tumors and cancer 
(Rowinsky et al., 1990; Rowinsky & Donehower, 1995) due to its ability to stabilize 
microtubules in the mitotic spindle and thus stopping the cell cycle in eukaryotic cells (Wani 
et al.,1971). The stabilization of microtubules is due to the specific bond between Taxol® and 
beta tubulin preventing microtubule depolymerization (Schiff et al., 1979). It has also been 
reported that Taxol® inhibits the process of angiogenesis (Wang et al., 2003). These Taxol® 
qualities have been taken as an advantage for the usage of this drug in killing carcinogenic 
cells in tumors. 
One of the main drawbacks of this molecule is its high hydrophobicity; making it practically 
insoluble in water which hinders their use in treatments inside the human body. In order to 
overcome such inconveniences, several strategies have been developed such as the use of 
adjuvants like Cremofor/Etanol (CrEL), solubilizant agent that facilitates the intravenously 
administration of the drug, process termed as chemotherapy. This technique has brought 
many disadvantages such as the fact of reducing considerably the drug’s diffusion capacity, 
making that a limited quantity of the drug be reached into the target site (Marupudi et al., 
2007), and therefore limiting the concentration level needed to eliminate tumors. To solve 
these inconveniences it has been resolved to increase the delivery cycles. The usage of 
Taxol® in CrEL and the high doses have produced undesired consequences with a 
numerous of hypersensitivity reactions and side effects including nausea, vomiting, 
urticaria, abdominal pain, diaphoresis, and other (Weiss et al., 1990; Wiernik et al., 1987). 
Looking for minimizing such secondary reactions, new options in the field of drug delivery 
are being explored. In the last decade a variety of drug delivery systems have been 
proposed as carriers of hydrophobic anticancer drugs. The list of these systems includes 
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drug loaded hydrogels, drug loaded nanoparticles, functionalized nanoparticles and some 
combined systems. Through this chapter we review the current trends for the transport and 
delivery of the most common anticancer drugs. Based in facts we point a delicate issue, 
Taxol crystallization in hydrogels and its negative impact, and finally we make a discussion 
about novel approaches for drug delivery against cancer.  
2. Hydrogels for drug delivery systems 
Currently the development of smart hydrogels that can respond to external stimuli such as 
variations in temperature, pH, and electric fields or hydrogels with controlled 
biodegradability has been used in biomedical applications. As such hydrogels are used in a 
wide range of applications including tissue engineering and regenerative medicine (Lee & 
Mooney, 2001), diagnosis (Van Der Linden et al., 2003), cell immobilization (Jen et al., 1996), 
bimolecular and cell separation (Wang et al., 1993), barriers to regulate the biological 
adhesion (Bennett et al., 2003). Hydrogels can be made, in theory, from any water-soluble 
polymer, encompassing a wide range of chemical compositions and physical properties. The 
polymer forms aggregates that form a three-dimensional matrix with interconnected pores 
in which the solvent (usually water or aqueous solutions) and other particles can diffuse 
(Figure 1). Some hydrogels have a high capacity to contain compounds that can be released 
in a controlled manner for therapeutic purposes. Its porosity allows the loading of drugs 
within the polymer matrix and their subsequent release at a rate that depends on the 
coefficient of diffusion of drug through the gel matrix in the case of hydrophilic drugs. For 
hydrophobic drugs, the rate of release depends on the rate of degradation of the gel. Besides 
their biodegradability can be designed to be via enzymatic, hydrolytic, or environmental 
(pH, temperature or electric fields). 
 
 
Fig. 1. Hydrogel structures observed by FESEM (Field Emission Scanning Electron 
Microscope). a) Chitosan-Glycerophosphate termosensitive hydrogel. Bar 40µm. b) Agarose 
hydrogel. Bar 250 nm.  
2.1 Thermosensitive hydrogels for anticancer drug delivery 
Commonly hydrogels gelatinize when their temperature drops; in other words they are 
present in a liquid state at higher temperatures, and they solidify when it drops. However, 
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there are hydrogels that exhibit the phenomenon of reverse thermal gelation, also known as 
thermally induced hydrogels. In this case they are liquid at lower temperatures, but they 
solidify when their temperature rises (Klouda & Mikos, 2008). This property has been 
exploited to create hydrogels that remain liquid at temperatures below 30 ° C, but they 
solidify at temperatures close to physiological temperature (37 °C). Therefore, they are 
better injected subcutaneously as a liquid and solidify when they reach body temperature. 
Some of these hydrogels are tri-block copolymer synthesized by open-ring polymerization 
such as poly (ethylene glycol)-poly(epsilon-caprolactone)-poly (ethylene glycol) (PEG-PCL-
PEG) (ChangYang et al., 2009; Yu, 2009), tri-block copolymer poly(ethylene oxide)-poly 
(oxidopropileno) -poly (ethylene oxide) (PEO-PPO-PEO) (Li & Li, 2008), and biopolymer 
chitosan (C) neutralized with b-glycerophosphate (GP) (Ruel-Gariépy et al., 2004). Most of 
these hydrogels are studied for drug delivery and some have already been used successfully 
for this purpose. For example, PEO-PPO-PEO-name Poloxamer 407 has been used to 
prolong the release of lidocaine (Chen et al., 2004). Also, some natural polymers exhibit the 
phenomenon of reverse thermal gelation such as those based on chitosan, which have 
reported positive results; for instance, a solution of chitosan with 40% weight of PEG has 
been tested on the release of serum bovine holding a sustained release of at least 70 hours 
(Bhattarai et al., 2005). Other organic hydrogels with this property are hydroxypropyl 
cellulose (Cai et al., 2003; Uraki et al., 2004) and methyl cellulose (Kumar et al., 1993).  
Among the new methods aimed to replace intravenous chemotherapy for the treatment of 
tumors there are certain proposals which emphasize the use of temperature-sensitive 
hydrogels loaded  with anticancer drugs. They suggest the injection of the thermosensitive 
hydrogels containing drug directly into the affected area (tumor), due to its reverse thermal 
behavior it solidifies inside the body and then the drug is released gradually. The most 
common proposed systems for Taxol® delivery have been those that offer direct 
incorporation of the drug into the thermosensitive hydrogel (Chun et al., 2009; Dai et al., 
2006; Kasala et al., 2008; Livnat et al., 2005; Marupudi et al., 2007; Ruel-Gariépy et al., 2004; 
Shi & Burt, 2004; Woo Sun et al., 2007). Just to mention some examples, the alginate 
hydrogel with polyethylene glycol (PEG) (Livnat et al., 2005), the hydrogel Dx-g-PCL result 
of the synthesis of polycaprolactone (PLC) and Dextran (Dextran70 and Dextran 500) (Shi & 
Burt, 2004), so as the thermosensitive chitosan-based hydrogel BST-Gel liquid (Marupudi et 
al., 2007). 
2.2 Paclitaxel crystallization in hydrogels  
We have studied Taxol® crystallization in aqueous solutions and hydrogels (Castro et al., 
2010). In both environments Taxol® forms needle-like crystals that grow concentrically 
forming complex morphologies such as spherulites, in the case of heterogeneous nucleation, 
or sheaves (axialites) when they are formed by homogeneous nucleation. In solution or gel 
these crystals can be observed by DIC (Differential Interference Contrast) microscopy or by 
fluorescent microscopy when they are labeled with a fluorescent dye such as rhodamine, as 
described in (Castro et al. 2009). Dried they can be analyzed by scanning electron 
microscopy (Figure 2). solution by heterogeneous nucleation with a Taxol concentration of 
50 µM. Sample was prepared by drying a drop in a TEM (Transmission Electron 
Microscope) cooper grid and then metalized by sputter coating with a gold-palladium 
target. a) Bar 2.5 µm, b) bar 10 µm.  
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The process of crystallization in aqueous solutions and hydrogels is quite similar and we 
can describe it in few words, Taxol crystallization follows the classical homogeneous 
nucleation theory. For low supersaturation (low Taxol concentrations), only a small number 
of crystals nuclei may form whereas for high supersaturation (>20 μM) the number of nuclei 
increases drastically with increasing Taxol® concentration.  
 
 
Fig. 2. Taxol crystals observed by FESEM. These crystals were obtained in aqueous solution. 
As we mentioned before, the most common Hydrogel-based Taxol® delivery systems 
reported in literature  suggest the direct incorporation of the drug into the thermosensitive 
hydrogel (Chun et al., 2009; Dai et al., 2006; Kasala et al., 2008; Livnat et al., 2005; Marupudi 
et al., 2007; Ruel-Gariépy et al., 2004; Shi & Burt, 2004; Woo Sun et al., 2007). But nobody, 
except Shi & Burt (2004), has reported Taxol crystallizacion in their systems. We claim that 
this phenomenon is present in most of these works, unfortunately this problem has been a 
neglected topic by many researchers and may go unnoticed because Taxol® crystals are not 
detectable by commonly used techniques for the characterization of the hydrogels. Perhaps, 
researchers have been concerned primarily in designing a good delivery system, neglecting 
other aspects of the drug, such as its crystallization. In studies reported in the literature that 
follow this line, no one takes into account, neither they mentioned nor reported studies of 
crystallization of Taxol® in hydrogels, despite that the use of the drug concentrations is 
greatly exceeded in its limit of solubility in aqueous solutions (0.77μM ) (Shi & Burt 2004).  
In order to provide evidence of Taxol crystallization in these hydrogels we have performed 
several experiments following similar conditions to that reported in the papers mentioned 
before. For instance we used similar hydrogels such as agarose, chitosan, poly (L-lactic acid) 
PLLA and thermosensitive Chitosan-Glycerophosphate and we also used Taxol 
concentrations similar, or even lower, to that reported in that works. As result we have 
found that Taxol® crystallization is always present in hydrogels and thermosensitive 
hydrogels (Figure 3). According to our observations Taxol® crystallization follows the 
behavior of the classical homogenous nucleation theory, as mentioned before. That means 
that at low Taxol concentrations (<30 µM) few but big (15-25 µm) axialites are present, while 
at higher many and smaller axialites are observed (Castro et al., 2011). Moreover paclitaxel 
crystals are very stable in aqueous environments. We have observed these crystals up to two 
months of formation without any noticeable change. Hence we can speculate that Taxol 
crystals inside the body probably would last for long time activating immune reactions. 
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Direct incorporation of paclitaxel into hydrogels can lead to crystallization of the drug 
which can dramatically decrease the therapeutic effects and effectiveness of paclitaxel 
delivery systems. Supporting our theory, we find in the work of Chun (2009) who reported 
that in vivo experiments with rats, contrary to what would be expected, the hydrogel with a 
lower concentration of Taxol® was more effective at tumor inhibition than hydrogel with 
the highest concentration. Although the authors did not provide explanations for such 
unexpected results, for us a good reason of this fact is the phenomenon of Taxol® 
crystallization, which is enhanced at higher concentrations. All this experimental evidence 
could be enough reason to believe that these systems do not meet the desired expectations 
and require major rethinking.  
 
 
Fig. 3. Taxol crystals formed in hydrogels. a) in aqueous solution, b) in agarose hydrogel, c) 
in poly (L-lactic acid) hydrogel, d) Chitosan-Glycerophosphate hydrogel. All samples 
prepared at a paclitaxel concentration of 100 µM.  
3. Nanoparticles for drug delivery 
In order to minimize the inconvenient of the hydrophobicity many authors have proposed 
the encapsulation of hydrophobic drugs in nanoparticles, this would allow increasing the 
amount of drug administered without using nasty solvents such as CrEL in the case of 
paclitaxel. Thus it is being explored new types of delivery systems based in nanocarriers 
such as micelles (You et al., 2008), nanoparticles (Liang et al., 2006), thin films (Shi & Burt, 
2004), and microspheres (Liu et al., 2007) among others (Ferrari & Downing, 2005), whose 
effectiveness is related to its size, modification of pharmacokinetics, biodistribution, 
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delivery control and toxicity reduction (Jun et al., 2008). Each one of these particles has 
unique characteristics that should be carefully analyzed taking into account the type of drug 
and the desired interaction to obtain the adequate system delivery. The liposome usage for 
delivery agent of the anticancer drugs is very broad, such as Doxil®, this drug is 
commercially distributed and used in several ovarian cancer treatments (Gordon et al., 
2001). However, the liposomes present several disadvantages due to their high permeability 
and stability in vivo (Conlin et al., 2009). Dendrimers are macromolecules characterized by 
their structural monodispersivity and symmetry. They consist of a central nucleus and its 
diverse ramifications. It contains different functional groups generally located on the 
exterior, which play an important role in their properties (Caminade et al., 2005). A 
disadvantage is its difficulty to be synthesized (Tomalia et al., 1990). The dendrimers are 
used in research studies for the prevention of sexually transmitted diseases (Zolnik & 
Sadrieh, 2009), as contrasting agents in Magnetic Resonance Imaging (Zolnik & Sadrieh, 
2009), combined with anticancer drugs (Malik et al., 1999), among other usages. The 
nanocapsules are vesicular systems with colloidal size, in which the drug is located inside 
and surrounded by a polymeric membrane (Soppimath et al., 2001). In this system, the 
nucleus consists of oily liquid and a simple polymeric layer covers it, this system has shown 
to be effective in encapsulating and releasing certain types  of hydrophobic drugs (Ameller 
et al., 2003). Nanospheres are solid colloidal particles in which the drug can be dissolved, 
encapsulated, conjugated or absorbed (Gref et al., 1995; Soppimath et al., 2001). They are 
generally larger than micelles and although its elimination is slow due to its hydrophobicity, 
are susceptible to renal filtration and the mono nuclear phagocyte system (MPS), It is 
therefore necessary to modify its surface (Letchford & Burt, 2007). Good stability has been 
achieved in nanospheres using amphiphilic copolymers (Gref et al., 1995), so it is possible 
the encapsulation of  the bioactive molecule at the core of the nanosphere (Yanasarn et al., 
2009), for example, it has been observed that the nanoparticles synthesized from emulsion of 
lecithin / water loaded with paclitaxel are more effective in attacking cancer cells than pure 
paclitaxel (Hu et al., 2009). In another study, gold nanoparticles encapsulated in 
nanospheres of chitosan and poly (acrylic acid) CS-PAA-Au have been used as delivery 
system drugs as well as for observation of cells (Latere et al., 2002). 
Within this range of particles could not miss the micelles, which have had a great interest in 
the issue of drug delivery and location into tumors (Lee et al., 2003; Yokoyama et al., 1999). 
Micelles are amphiphilic molecules consisting of hydrophilic and hydrophobic segments. Its 
outer layer, which is highly hydrated, provides stability in aqueous environments, while the 
hydrophobic core allows the incorporation of water-insoluble drugs. Moreover, if the 
polymeric micelles have a diameter ranging from 10 to 100nm allows long circulation in the 
bloodstream avoiding defenses of the mono nuclear phagocyte system and suppressing 
renal clearance. They can be large enough to avoid being excreted by the kidneys but small 
enough to pass the interendothelial cell filtration (Yang et al., 2009). 
As a result, drug activity continues after a single application over a long period of time. In 
addition, these micelles remain intact at levels below the critical micelle concentration 
(CMC), so they retain their structure and preferentially accumulate in solid tumors via the 
permeability and retention effect (EPR) (Nakayama et al., 2007; Saez et al., 2004). Its 
amphiphilic nature gives them a central place in the area of the release of hydrophobic 
drugs, due to its excellent drug storage capacity in its core. 
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The hydrophobic core also has other important features such as protecting the drug from 
being deactivated by enzymes or other bioactive species from the aqueous medium (blood 
fluid) (Wilhelm et al., 1991; (Yokoyama et al., 1990). Also, this medium affects the rate of 
drug release, in many cases declining it, as the release rate is controlled both by the stability 
of the micelles as the hydrophobicity of their core and the chemical species used to attach 
the drug to the polymer backbone. These factors may be independent of the properties of 
the drug.  
While each system has its advantages and disadvantages, micelles and nanospheres formed 
by amphiphilic copolymers have greater flexibility in their synthesis and uses, and they 
have had good results with hydrophobic drugs. The difference lies in the method of 
preparation and length of the hydrophobic segment. Although for some authors the 
nanospheres are systems that perform in vivo by presenting better retention properties of 
the drug, they have a burst effect when the drug is readily released; in this sense, the 
nanospheres are overcome by the micelles who exhibit more stable behaviors (Gaucher et 
al., 2010; Kwon, 2003). We can mention some examples of micelles made of different 
polymers used to carry drugs. We cite a few micelles synthesized from copolymer PEG-
PASP-DMEDA loaded with ammonium glycyrrhizate (AMG) poorly water soluble drug 
used against Hepatitis C (Yang et al., 2009). Copolymer polylactide / polyethylene glycol is 
synthesized by polymerization of ring-opened was used to encapsulate paclitaxel without 
the presence of an organic solvent (Kim et al., 2009). Also, some micelles are sensitive to 
changes in pH, this feature can be used to control drug release as self-assembled micelles of 
copolymer PEG-b-PMA with divalent metals loaded with doxorucibin (Li et al., 2009). 
Tamoxifen and paclitaxel have also been charged in micelles with a hydrophilic block of 
poly [2 - (ethyl methacriloyloxi) phosphorylcholine] (MPC), hydrophobic block and a pH 
sensitive poly [2 - (diisopropylamine)ethyl methacrylate] (DPA) (FA-MPC-DPA) (Licciardi 
et al., 2008). Doxorubicin was loaded using thermosensitive blocks such as poly (N-
isopropylacrylamide-co-N, N-dimethyl-acrylamide) in which the hydrophobic part was 
synthesized from poly (D, L-lactide), poly(epsilon-caprolactone) or poly (D, L-lactide-co-ԑ-
caprolactone) (Masamichi et al., 2006). Another type of thermosensitive micelles have been 
synthesized from poly (N-isopropylacrylamide) and poly (butyl methacrylate) also loaded 
with doxorubicin (Chung et al., 1999). Similarly, micelles have been developed and modified 
in the copolymer as synthesized from poly (ethylene glycol)-poly (aspartateester groups 
heptyl, nonyl, phenyl propyl benzyl and for greater stabilization of the drug N-(4 - 
hydroxifenil) retinamide (Tomoyuki et al., 2008).  
Encapsulation of paclitaxel in nanoparticles is very promising and results have been 
favorable, judging by the reports in the literature. However, most authors suggest the use of 
nanoparticles to be injected into the bloodstream, following the route of traditional 
chemotherapy, which somehow still has the disadvantage of low specificity in which the 
problem is attacked. But that's not all, perhaps the main problem is not the lack of specificity 
of the method, but the risk involved in the use of nanoparticles in the bloodstream. 
Currently, no one knows for sure the adverse effects of the use of nanoparticles in the 
bloodstream, since its size could pass biological membranes or barriers and it has unknown 
effects on areas of the body, becoming a health risk factor , as noted by experts on the 
subject of the risks of nanotechnology in medicine (Scott et al., 2008). To this, we must add 
that the nanoparticles contain a highly cytotoxic drug.  
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3.1 Functionalization of nanoparticles 
Particle functionalization with specific ligands for cancer cells has gained considerable 
attention for those looking for more specificity in their systems carrying the drug. Work is 
being currently done to prove their effectiveness with different ligand-receptor systems in a 
variety of cancer cell lines to test the efficiency of the functionalization of these systems. The 
effectiveness of the functionalization of nanoparticles lies in the premise of the existence of 
certain molecules in tumors are different from those found in normal tissues and can be 
identified as biomarkers of tumorogenesis (Mohd & Mohammad, 2009). Depending on its 
test site, they may be biomarkers of tissue or circulatory. Tissue biomarkers have different 
categories such as membrane receptors, oncogenes, tumor suppressor genes, nucleic 
antigens, growth factors and components of degradation. Circulatory biomarkers include a 
broad category of tumor-associated antigens (TAA). Selective biomarkers can identify risks 
and help tumor detection, and an early diagnosis allows appropriate therapeutic 
interventions for an effective treatment. In addition to these biomarkers, it is also common 
to find an over expression of certain proteins membrane in cancer cells, which has been used 
for the use of specific ligands or molecules to these proteins, such as folic acid to folate 
receptors, to obtain greater interaction of nanoparticles to cancer cells. In this case, the 
effectiveness of the functionalization is more a matter of statistics than specificity by itself, 
since having the over expression of these receptors will increase the likelihood of attracting 
a greater number of drug-loaded nanoparticles to diseased cells.  
Micelles have been recently reported to have been functionalized with folic acid as a specific 
ligand , which is strongly attracted to its receptor in the cell membrane. The folate receptor 
is a protein that is generated in large quantities during cell proliferation in several types of 
cancer cells such as ovarian, breast, brain and lung (Ross et al., 1994).  
Also, peptides have been used for the functionalization of micelles as locators of cancer cells. 
The nature of polypeptides allows performance optimization of specific ligands by adjusting 
the sequence or conformation of the peptides. One example is the peptide cRGD (cyclic Arg-
Gly-Asp-D-Phe-Lys) specific for ǂvǃ3 receptor produced in large amounts in tumor 
endothelial cells (Nasongkla et al., 2004). These receptors are a cell membrane protein that is 
affected with the growth of tumors, local invasiveness and potentially in metastasis, but it is 
not detected in quiescent vessels (Rueg et al., 2002; Teti et al., 2002; Vamer & Cheresh, 1996). 
This membrane receptor increases its levels in vascular angiogenesis, thus making tumor 
treatment specific for the generation of new blood vessels (Wermuth et al., 1997). 
Carbohydrate functionalized micelles, asialoglycoprotein receptor (ASGPR) is a recipient of 
lecithin membrane commonly found in liver cells (Ashwelland & Harford, 1982). In 
hepatocellular  carcinoma are high levels of (ASGPR), which helps the specificity of 
chemotherapy for liver (Wands & Blum, 1991). Carbohydrate molecules such as galactose 
and mannose are specific ligands of this receptor (Goto et al., 1994; Jansen et al., 1991).  
The use of antibodies as specific ligands is promising as they are able to bind to a range of 
specific antigens in cancer cells. The combination of a brain-specific antibody increased to 5-
fold the neuroleptic action in charged micelles than in non-functionalized micelles, and it is 
20 times greater than for the free drug (Kabanov et al., 1989). Micelles have been reported 
(PEG-PE) functionalized with 2 antibodies, a monoclonal anti-cancer antibody (mAb2C5) 
and anti-myosin (mAb2G4). Both antibodies have great ability to bind to the substrates after 
conjugation of the micelles. The antibody 2C5 in micelles loaded with paclitaxel increased 4 
times the drug accumulation in the tumor after 2 hours (Torchilin et al., 2003). Furthermore, 
there is the functionalization of micelles with aptamers. The aptamers are DNA and RNA 
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oligonucleotides that can identify a large number of specific molecules (Torchilin et al., 2003; 
Tuerkand & Gold, 1990). We have seen that PEG-PLA micelles with an RNA aptamer 
specifically bind to an antigen on the membrane of prostate tumor (PSMA). Nanoparticles 
with the induction of aptamer showed 77 times more specificity to PSMA receptor than non-
functionalized particles (Ellingtonand & Szostak, 1990). The use of ligands has yielded 
promising results for the location of cancer cells. This will allow drug release systems based 
on nanoparticles using different ligands that recognize different types of cancer. There is 
further research to look for future and further specific treatments with low or no side effects.  
Instead of using a single ligand, nanoparticles’ specificity can be potentiated using multiple 
ligands in a single particle. Sooner or later, these systems will have the ability to attack 
different cancers at once or they will be designed to exchange specific ligands in an easy 
way, having a generic nanoparticle system capable of receiving any desired ligand 
presenting a universal binding system.  
4. Combined systems based on hydrogels and nanoparticles 
There are few studies that have integrated particles or micelles loaded with Taxol® in 
thermosensitive hydrogels. As good examples we can mention the system proposed by 
Jiang Liu et al. (2007) (Liu et al., 2007). This system consists of a biodegradable gelatin 
sponge containing PLGA-PTX microspheres (polylactide-co-glycolic acid-paclitaxel) in order 
to provide continuous local release of PTX (paclitaxel). They obtained a more prolonged 
release rate for up to 19 days, in contrast to simple systems where the paclitaxel was 
released within a range less than one hour. In another study presented by Yang Yang et al. 
(2009) joined Docetaxol (DTX) in a pluronic gel F127(PF127) injectable thermosensitive 
mixed micelles prepared with the same material (PF127) and loaded with Taxol® (system 
GMM). During a test of 156 hours, it was found that the proposed system maintains a 
prolonged release of DTX compared with other control systems (Yang et al., 2009). 
The development of combined drug delivery systems based on efficient and innovative 
drug encapsulation in functionalized nanoparticles to detect and attack cancer cells, using 
thermosensitive hydrogels as vehicles that can be injected locally can be an excellent option 
for the treatment of cancerous tumors, thereby eliminating the supply of intravenous drugs 
and consequently the severe side effects. Specifically for Taxol®, its encapsulation in 
nanoparticles would prevent crystallization when deposited in the hydrogel. In addition, 
the release rates could be controlled in a double form, both by the action of the degradation 
of gel particles released and at the same time by the degradation of the particle containing 
the Taxol®. Achieving prolonged drug release would increase the therapeutic effects for 
longer periods. An added value to these systems is the funcionalization or even 
multifuncionalization of nanoparticles with ligands or antibodies for high specificity to 
cancer cells, which should increase the efficiency and the therapeutic effectiveness of the 
system. Even today very few researchers have worked with Taxol® delivery systems with 
the characteristics listed above; making this theme of the project attractive and innovative 
for study. 
5. Conclusions  
Researchers are currently exploring new methods for transport and controlled release of 
drugs for cancer treatment, thereby seeking to reduce the side effects the of currently 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
776 
applied chemotherapy as well as looking for battling more efficiently and accurately such 
disease. Although there are a number of published research focused on this issue, the fact is 
that so far no systems have emerged to prove conclusively its efficacy, although always 
positive progress has been shown, each proposed system suffers from certain drawbacks 
that slows down the progress towards real applications. The disadvantages found in the 
systems of transport and release of anticancer drugs proposed in recent years can be 
overcome by taking advantage of each method and combining them into drug delivery 
systems composed with more sophistication and complexity than their predecessors. This 
idea has already begun to be implemented by some researchers who have integrated drug-
loaded nanoparticles on thermosensitive hydrogels (Liu et al., 2007), but these authors have 
not exploited the alternative of functionalization or multi-functionalization of nanoparticles. 
So, there is still much room for much improvement in these drug delivery systems and it is 
where researchers could find novel ideas. For example we can think in to make 
functionalized or multifunctionalized nanoparticles loaded with a anticancer drug, then 
incorporate them into a thermosensitive hydrogel. With this proposed system, the hydrogel 
may be injected into the tumor area (in the case of solid tumors) and gradually 
functionalized nanoparticles will be released. Due to its functionalization, they will be 
attracted mainly to diseased cells, nanoparticles will be biodegraded and drug will be 
released surrounding the cell. There are several advantages of using combined systems. For 
example, the highly localized application by avoiding the bloodstream, in the case of solid 
tumors; an improved release profile with a slow and steady dose that highly favored the 
drug's effectiveness in eliminating cells. The effectiveness of the functionalization of 
nanoparticles will be favored by the close application to malignant cells; in general, we will 
expect to acquire treatments where the typical collateral damage observed in common 
chemotherapies would be considerably lower as well as the required dose. 
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